Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06787586 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
A Phase 1 study of Atopic Dermatitis (AD) and Normal Volunteers, sponsored by Attovia Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 17
- Study locations
NCT06787586 is a Phase 1 study of Atopic Dermatitis (AD) and Normal Volunteers that is active but no longer recruiting, run by Attovia Therapeutics. The registered enrollment target is 108 participants, above the 95-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (14% higher). The trial reports 17 study locations across 10 states.
The verdict
NCT06787586, a Phase 1 study of Atopic Dermatitis (AD) and Normal Volunteers, is active but no longer recruiting, sponsored by Attovia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 17
- Study locations
Study Summary
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Conditions Studied
Interventions
- DRUG ATTO-1310
- DRUG ATTO-1310 Placebo
Study Locations (17)
California
- Attovia Clinical Site 103 - Encinitas
- Attovia Clinical Site 116 - Rocklin
- Attovia Clinical Site 107 - Sacramento
Ontario
- Attovia Clinical Site 111 - Newmarket
- Attovia Clinical Site 112 - Peterborough
- Attovia Clinical Site 113 - Toronto
Florida
- Attovia Clinical Site 109 - Coral Gables
- Attovia Clinical Site 118 - Margate
New York
- Attovia Clinical Site 114 - New York
- Attovia Clinical Site 119 - New York
Quebec
- Attovia Clinical Site 105 - Montreal
- Altasciences - Montreal
Indiana
- Attovia Clinical Site 102 - Plainfield
Missouri
- Attovia Clinical Site 104 - Saint Joseph
Nevada
- Attovia Clinical Site 106 - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06787586
The ClinicalTrials.gov registry entry for NCT06787586 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 95-participant average among 7 other Atopic Dermatitis (AD) trials with a reported enrollment target (14% higher). The listed sponsor is Attovia Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Atopic Dermatitis (AD) appearing as the primary indexed condition, and to 2 interventions - of which ATTO-1310 is the first listed.
NCT06787586 reports 17 study locations spanning 10 distinct geographic areas - top geographies include California, Ontario, Florida.
Frequently Asked Questions
What is clinical trial NCT06787586 about?
NCT06787586 is a clinical study titled "Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus". The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310...
What is the current status of trial NCT06787586?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2025-01-14. Estimated completion is 2026-05.
What conditions does trial NCT06787586 study?
This clinical trial studies the following conditions: Atopic Dermatitis (AD), Normal Volunteers, Atopic Eczema, Chronic Pruritus.
What interventions are being tested in trial NCT06787586?
The interventions under investigation include: ATTO-1310 (DRUG), ATTO-1310 Placebo (DRUG).
Who is sponsoring clinical trial NCT06787586?
This trial is sponsored by Attovia Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06787586 being conducted?
This trial has 17 study locations across California, Florida, Indiana, Missouri, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis (AD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
RECRUITING · Phase 1
-
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
RECRUITING · Phase 1
-
The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
RECRUITING · Phase 1
-
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 1
-
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.